

2020 Regular Session

HOUSE BILL NO. 263

BY REPRESENTATIVE HUVAL

DRUGS/PRESCRIPTION: Provides for insurance coverage of step therapy or fail first protocols

1 AN ACT

2 To amend and reenact R.S. 22:1053, relative to coverage of step therapy or fail first
3 protocols; to provide for clinical review criteria and use of clinical practice
4 guidelines to be used as minimum standards in developing a step therapy or fail first
5 protocol; to provide for clarification on providers lawfully allowed to prescribe; to
6 provide for an override request process for restricted prescription drugs; to provide
7 for override clinical evidence; to provide for decision-making timelines; to provide
8 for appeal rights; to provide for definitions; to provide for technical changes; and to
9 provide for related matters.

10 Be it enacted by the Legislature of Louisiana:

11 Section 1. R.S. 22:1053 is hereby amended and reenacted to read as follows:

12 §1053. Requirement for coverage of step therapy or fail first protocols

13 A. Any health coverage plan specified in Subsection ~~H~~ L of this Section
14 which includes prescription benefits as part of its policy or contract, which utilizes
15 step therapy or fail first protocols, and which is issued for delivery, delivered,
16 renewed, or otherwise contracted for in this state on or after January 1, ~~2011~~ 2020,
17 shall comply with the provisions of this Section.

18 B.(1) Any step therapy or fail first protocol established by a health coverage
19 plan shall consider clinical review criteria and clinical practice guidelines that are
20 developed and endorsed by a multidisciplinary panel of experts who manage

1 conflicts of interest among the members of writing and review groups by doing all
2 of the following:

3 (a) Requiring members to disclose any potential conflicts of interest with
4 health coverage plans or pharmaceutical manufacturers and to recuse themselves
5 from voting if they have a conflict of interest.

6 (b) Using a methodologist to work with writing groups to provide objectivity
7 in data analysis and ranking of evidence through the preparation of evidence tables
8 and facilitating consensus.

9 (c) Offering opportunities for public review and comments.

10 (d) Creating an explicit and transparent decisionmaking process.

11 (e) Basing decisions on high quality studies, research, peer-reviewed
12 publications, and medical practice.

13 (f) Minimizing biases and conflicts of interest.

14 (g) Explaining the relationship between treatment options and outcomes.

15 (h) Rating the quality of the evidence supporting recommendations.

16 (i) Considering relevant patient subgroups and preferences.

17 (j) Considering the needs of atypical patient populations and diagnoses when
18 establishing clinical review criteria.

19 (k) Recommending that the prescription drugs be taken in the specific
20 sequence required by the step therapy protocol.

21 (l)(i) Continuously reviewing new evidence, research, and newly developed
22 treatments to update the clinical review criteria and clinical practice guidelines.

23 (ii) If clinical practice guidelines are not reasonably available, any step
24 therapy or fail first protocol established by a health coverage plan shall consider
25 peer-reviewed publications or expert guidance from independent experts, which may
26 include practioners with expertise applicable to the relevant health condition.

27 (2) This Subsection shall not be construed to require health coverage plans
28 to establish a new entity to develop clinical review criteria used for step therapy or
29 fail first protocols.

1 C. When medications for the treatment of any medical condition are
2 restricted for use by ~~an insurer~~ by any health coverage plan through a step therapy
3 or fail first protocol, the prescribing ~~physician~~ practitioner shall have access to a
4 clear and convenient process to expeditiously request an override of ~~such~~ the
5 restriction ~~from the insurer~~. The override process shall be made easily accessible on
6 the health coverage plan's website. An override of ~~such~~ the restriction shall be
7 expeditiously granted by the ~~insurer~~ under health coverage plan if the prescribing
8 practitioner, using sound clinical evidence, can demonstrate any of the following
9 circumstances:

10 (1) ~~The prescribing physician can demonstrate to the health coverage plan,~~
11 ~~based on sound clinical evidence, that the~~ The preferred treatment required under the
12 step therapy or fail first protocol has been ineffective in the treatment of the insured's
13 patient's disease or medical condition. The prescribing practitioner shall demonstrate
14 to the health coverage plan that the patient has tried the required prescription drug
15 while under his current or a previous health insurance or health coverage plan, or
16 another prescription drug in the same pharmacologic class or with the same
17 mechanism of action, and the prescription drug was discontinued due to lack of
18 efficacy or effectiveness, diminished effect, or an adverse event.

19 (2) ~~The prescribing physician can demonstrate to the health coverage plan,~~
20 ~~based on sound clinical evidence, that the~~ The preferred treatment required under the
21 step therapy or fail first protocol is reasonably expected to be ineffective based on
22 the known relevant physical or mental characteristics and medical history of the
23 insured patient and known characteristics of the drug regimen.

24 (3) ~~The prescribing physician can demonstrate to the health coverage plan,~~
25 ~~based on sound clinical evidence, that the~~ The preferred treatment required under the
26 step therapy or fail first protocol will cause is contraindicated or will likely cause an
27 adverse reaction or ~~other~~ physical or mental harm to the insured patient.

1 (4) The patient is stable on a prescription drug selected by his healthcare
2 provider for the medical condition under consideration while on a current or previous
3 health insurance or health coverage plan.

4 (5) The required prescription drug is not in the best interest of the patient
5 based on medical necessity as evidenced by valid documentation submitted by the
6 prescriber.

7 D. Approval of a step therapy or fail first protocol override request, when
8 issued by a health coverage plan, shall include clear authorization of coverage for the
9 prescription drug prescribed by the patient's prescribing practitioner.

10 E. Denial of a step therapy or fail first protocol override request shall not be
11 considered a final adverse determination and shall be eligible for an appeal of
12 coverage determination pursuant to R.S. 22:2401.

13 F. A health coverage plan shall approve or deny a step therapy or fail first
14 protocol override request, or an appeal of a step therapy or fail first protocol
15 override, within seventy-two hours of receipt. In cases where exigent circumstances
16 exist, a health coverage plan shall approve or deny a step therapy or fail first protocol
17 override request within twenty-four hours of receipt. If a health coverage plan fails
18 to comply with the timelines provided for in this Subsection, the override request
19 shall be considered approved.

20 G. In the case of a denial, the health coverage plan shall provide the patient
21 and the prescribing practitioner with the reason for the denial, an alternative covered
22 medication, if applicable, and information regarding the procedure for submitting an
23 appeal to the denial.

24 H. In the case of an appeal, the practitioner or, if appropriate, other
25 healthcare provider deciding the appeal shall consider atypical diagnoses and the
26 needs of atypical patient populations.

27 ~~€~~ I. The duration of any step therapy or fail first protocol shall not be longer
28 than the customary period for the medication when ~~such~~ the treatment is
29 demonstrated by the prescribing ~~physician~~ practitioner to be clinically ineffective.

1 When the health coverage plan can demonstrate, through sound clinical evidence,
2 that the originally prescribed medication is likely to require more than the customary
3 period for ~~such~~ the medication to provide any relief or an amelioration to the ~~insured~~
4 patient, the step therapy or fail first protocol may be extended for an additional
5 period of time no longer than the original customary period for the medication.

6 ~~D.~~ J.(1) No health coverage plan shall use step therapy or fail first protocols
7 as the basis to restrict any prescription benefit for the treatment of stage-four
8 advanced, metastatic cancer or associated conditions if at least one of the following
9 criteria is met:

10 ~~(1)~~(a) The prescribed drug or drug regimen has the United States Food and
11 Drug Administration approved indication.

12 ~~(2)~~(b) The prescribed drug or drug regimen has the National Comprehensive
13 Cancer Network Drugs and Biologics Compendium indication.

14 ~~(3)~~(c) The prescribed drug or drug regimen is supported by peer-reviewed,
15 evidenced-based medical literature.

16 ~~E.~~(2) The provisions of this Subsection ~~D of this Section~~ shall not apply if
17 the preferred drug or drug regimen is considered clinically equivalent for therapy,
18 contains the identical active ingredient or ingredients, and is proven to have the same
19 efficacy. For purposes of this Subsection, different salts proven to have the same
20 efficacy shall not be considered as different active ingredients.

21 ~~F.~~(3) For drugs prescribed for associated conditions as defined in this
22 Section, the treating healthcare provider shall inform the health coverage plan that
23 the condition is a condition associated with stage-four advanced, metastatic cancer
24 when requesting authorization.

25 ~~G.~~ K.(1) If a prescribed drug is denied by a health coverage plan based upon
26 step therapy or fail first protocols, the health coverage plan shall provide the
27 prescriber with a list of the alternative comparable formulary medications in writing
28 and attached to the letter of denial of prescription drug coverage.

1 (2) It shall be deemed sufficient to meet the requirements of this Subsection
2 if a health coverage plan includes the information required by this Subsection in the
3 denial letter sent by the health coverage plan or its agent. For any request made by
4 providers utilizing electronic health records with capabilities, the notice may be sent
5 electronically.

6 (3) Simple notification of the availability and location of the formulary shall
7 not be deemed sufficient to meet the requirements of this Subsection.

8 L. As used in this Section, the following definitions shall apply:

9 (1) "Health coverage plan" means:

10 (a) An individual or group plan or program which is established by contract,
11 certificate, law, plan, policy, subscriber agreement, or by any other method and
12 which is entered into, issued, or offered for the purpose of arranging for, delivering,
13 paying for, providing, or reimbursing any of the costs of health or medical care,
14 including pharmacy services, drugs, or devices.

15 ~~H.(1)(a) As used in this Section, a "health coverage plan" shall mean any~~

16 (b) Any hospital, health, or medical expense insurance policy, hospital or
17 medical service contract, employee welfare benefit plan, contract or agreement with
18 a health maintenance organization or a preferred provider organization, health and
19 accident insurance policy, or any other insurance contract of this type, including a
20 group insurance plan and the Office of Group Benefits programs.

21 ~~(b)(c) "Health coverage plan" shall include any~~ Any plan that is subject to
22 the provisions of this Section which is administered by a pharmacy benefit manager.

23 (2) ~~As used in this Section, "stage-four~~ Stage-four advanced, metastatic
24 cancer" means cancer that has spread from the lymph nodes or other areas or parts
25 of the body:

26 (3) ~~As used in this Section, and~~ and "associated conditions" means the symptoms
27 or side effects associated with stage-four advanced, metastatic cancer or its
28 treatment.

DIGEST

The digest printed below was prepared by House Legislative Services. It constitutes no part of the legislative instrument. The keyword, one-liner, abstract, and digest do not constitute part of the law or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]

HB 263 Engrossed

2020 Regular Session

Huval

Abstract: Provides for clinical review criteria and use of clinical practice guidelines to be used as minimum standards in developing a step therapy or fail first protocol and a process to request an override of step therapy or fail first protocol requirements.

Present law establishes certain requirements for implementation of step therapy or fail first protocols used by any health coverage plan.

Proposed law retains present law and further requires the development of the step therapy or fail first protocol to be based on clinical review criteria and clinical practice guidelines that are developed and endorsed by a multidisciplinary panel of experts based on certain identified criteria.

Proposed law does not require the health coverage plan to establish a new entity to develop clinical review criteria.

Present law provides for a step therapy or fail first protocol override process to be used by prescribing physicians.

Proposed law retains present law but adds the requirement that the override process be accessible on the health coverage plan's website and expands the permitted prescriber class from a physician to a practitioner.

Present law provides for an opportunity for the prescriber to demonstrate to the health coverage plan that the preferred treatment has been ineffective in treating the disease or mental condition of the insured.

Proposed law retains present law and provides additional criteria in which a prescriber can demonstrate that the patient tried the required prescription drug under a current or prior health coverage plan, or another drug in the same drug class, and it was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event.

Present law provides the prescriber with an opportunity to demonstrate to the health coverage plan that the preferred treatment will cause or will likely cause an adverse reaction or other physical harm to the patient.

Proposed law retains present law and further allows the prescriber to demonstrate that the preferred treatment is contraindicated or will cause mental harm to the patient, that the patient is stable on a certain prescription drug, or that the preferred drug is not in the best interest of the patient based on medical necessity.

Proposed law requires for a drug deemed not in the best interest of the patient, based on medical necessity, to be evidenced by valid documentation submitted by the prescriber.

Proposed law requires a health coverage plan to approve or deny a step therapy or fail first protocol override request within 72 hours of receipt, except, in exigent circumstances, the health coverage plan shall approve or deny a step therapy or fail first protocol override request within 24 hours of receipt. Proposed law provides that failure by a health coverage plan to comply with the timelines in proposed law shall cause the override request to be considered approved.

Proposed law requires a practitioner or healthcare provider, in the case of an appeal, to consider atypical diagnoses and the needs of atypical patient populations when deciding on appeals.

Proposed law requires a health coverage plan, if the plan denies an override request, to provide the prescribing practitioner and the patient with the reason for the denial, an alternative covered medication, and information regarding the procedure for submitting an appeal of the denial.

Proposed law updates definitions for "health coverage plan" and "stage-four advanced, metastatic cancer".

(Amends R.S. 22:1053)

Summary of Amendments Adopted by House

The Committee Amendments Proposed by House Committee on Insurance to the original bill:

1. Clarify that a multidisciplinary panel of experts will review and research certain treatments to update clinical review criteria and clinical practice guidelines.
2. Require for a drug deemed not in the best interest of the patient, based on medical necessity, to be evidenced by valid documentation submitted by the prescriber.
3. Require a practitioner or healthcare provider, in the case of an appeal, to consider atypical diagnoses and the needs of atypical patient populations when deciding on appeals.
4. Make technical changes.